New drug combo aims to keep lung cancer in check after initial treatment

NCT ID NCT07545954

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen after first-line treatment will receive the combination as maintenance therapy. The main goal is to check safety and tolerability, with a secondary look at how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DSP-0390 (a cholesterol synthesis inhibitor) and atezolizumab (an immunotherapy drug)
What this could lead to
If this combination is safe and shows promise, it could lead to a new maintenance treatment option to help keep extensive stage small cell lung cancer from progressing after initial therapy.
What could go wrong
This is a very early, small pilot study with only 20 participants. The combination may cause side effects or not work better than current standard care. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.